Reversal of progressive renal allograft dysfunction with OKT3

J. F. Burdick; L. R. Pennington; W. Smith; B. Irwin; G. M. Williams

doi:10.1159/000184435

Reversal of progressive renal allograft dysfunction with OKT3

J. F. Burdick, L. R. Pennington, W. Smith, B. Irwin, G. M. Williams

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The safety and efficacy of treatment with Orthoclone OKT3 was evaluated in 14 renal transplant patients with allograft dysfunction unresponsive to conventional therapy. Eleven of the 14 initially improved on OKT3, and 9 have retained their kidneys after a median 13-month follow-up. The mean serum creatinine among successes is 2.4 mg/dl. It is concluded that OKT3 is a safe and effective drug for treatment of rejection, and may be used during temporary discontinuation of ciclosporin in cases in which nephrotoxicity is questioned.

Original language	English (US)
Pages (from-to)	52-55
Number of pages	4
Journal	Nephron
Volume	46
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1159/000184435
State	Published - 1987
Externally published	Yes

ASJC Scopus subject areas

Physiology
Nephrology
Physiology (medical)
Urology

Access to Document

10.1159/000184435

Cite this

@article{afdb44773af94b2e948e19097757e9cd,

title = "Reversal of progressive renal allograft dysfunction with OKT3",

abstract = "The safety and efficacy of treatment with Orthoclone OKT3 was evaluated in 14 renal transplant patients with allograft dysfunction unresponsive to conventional therapy. Eleven of the 14 initially improved on OKT3, and 9 have retained their kidneys after a median 13-month follow-up. The mean serum creatinine among successes is 2.4 mg/dl. It is concluded that OKT3 is a safe and effective drug for treatment of rejection, and may be used during temporary discontinuation of ciclosporin in cases in which nephrotoxicity is questioned.",

author = "Burdick, {J. F.} and Pennington, {L. R.} and W. Smith and B. Irwin and Williams, {G. M.}",

year = "1987",

doi = "10.1159/000184435",

language = "English (US)",

volume = "46",

pages = "52--55",

journal = "Nephron",

issn = "0028-2766",

publisher = "S. Karger AG",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Reversal of progressive renal allograft dysfunction with OKT3

AU - Burdick, J. F.

AU - Pennington, L. R.

AU - Smith, W.

AU - Irwin, B.

AU - Williams, G. M.

PY - 1987

Y1 - 1987

N2 - The safety and efficacy of treatment with Orthoclone OKT3 was evaluated in 14 renal transplant patients with allograft dysfunction unresponsive to conventional therapy. Eleven of the 14 initially improved on OKT3, and 9 have retained their kidneys after a median 13-month follow-up. The mean serum creatinine among successes is 2.4 mg/dl. It is concluded that OKT3 is a safe and effective drug for treatment of rejection, and may be used during temporary discontinuation of ciclosporin in cases in which nephrotoxicity is questioned.

AB - The safety and efficacy of treatment with Orthoclone OKT3 was evaluated in 14 renal transplant patients with allograft dysfunction unresponsive to conventional therapy. Eleven of the 14 initially improved on OKT3, and 9 have retained their kidneys after a median 13-month follow-up. The mean serum creatinine among successes is 2.4 mg/dl. It is concluded that OKT3 is a safe and effective drug for treatment of rejection, and may be used during temporary discontinuation of ciclosporin in cases in which nephrotoxicity is questioned.

UR - http://www.scopus.com/inward/record.url?scp=0023179203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023179203&partnerID=8YFLogxK

U2 - 10.1159/000184435

DO - 10.1159/000184435

M3 - Article

C2 - 2957603

AN - SCOPUS:0023179203

SN - 0028-2766

VL - 46

SP - 52

EP - 55

JO - Nephron

JF - Nephron

IS - SUPPL. 1

ER -

Reversal of progressive renal allograft dysfunction with OKT3

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this